Audio Journal of Oncology, February 26th, 2008 Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma MARTIN DREYLING, University Hospital Grosshaden, Munich REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.

Audio Journal of Oncology, February 26th, 2008 "Total Therapy" Possible Cure For Multiple Myeloma? BART BARLOGIE, University of Arkansas, Little Rock REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 A treatment known as "total therapy" could cure many patients with multiple myeloma, conference-goers have just heard. The targeted drugs thalidomide and bortezomib, coupled with tandem autologous transplants, are used by Arkansas-based Bart Barlogie. In Paris he told Peter Goodwin about their success.

Audio Journal of Oncology, February 26th, 2008 Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 Multiple myeloma may soon be considered a chronic disease with cure on the horizon, thanks to an array of novel therapies which are turning prospects around for this malignancy. So said Kenneth Anderson at the European meeting in Paris. He explained to Peter Goodwin how a number of molecular and other therapies are changing the prospects for this disease.

Audio Journal of Medicine, January 11th, 2008 Meta-Analysis Proves Statins Help Patients With Diabetes COLIN BAIGENT, Oxford University REFERENCE: Lancet 371:117 January 11, 2008 Statins were foiund to cut cardiovascular event rates by a fifth among patients with both Type I and Type II diabetes in a meta-analysis of 18 000 patients from Oxford University in England and the University of Sydney in Australia. Peter Goodwin asked the lead UK investigator, Colin Baigent, about the findings and their implications.

Audio Journal of Medicine, January 4th, 2008 Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability PETER TYRER, Imperial College, W6 8RP London REFERENCE: Lancet 371:57 January 5, 2008 A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients who have intellectual disability presenting with a syndrome commonly labelled as "aggressive challenging behaviour" has shown that the anti-psychotic medicines gave no benefit. Peter Goodwin met up with Professor Peter Tyrer at London's Imperial College to ask him about the study.

5 of 176 episodes displayed
View All Episodes >
(171 more)